StockData
Royalty Pharma plc logo

Royalty Pharma plc (RPRX) stock

RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 8/3048% above fair value
$67.18+1.25 (+1.90%)

Close on Oct 30, 2026Market cap $38.63BP/E 38.2Yield –

Earnings

Royalty Pharma's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 4, 2026
Q3 FY2026 · estimated, before the open
Revenue, Q2 FY2026
$674.00M
+16.4% on a year earlier
EPS, Q2 FY2026
–
Latest guidance
Raised
Aug 5, 2026 · 5 items

Quarterly results

Revenue and earnings per share from each of Royalty Pharma's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Nov 4, 2026Expected––––
Q2 FY2026ended Jun 30, 2026Aug 5, 2026before the open$674.00M+16.4%–Release
Q1 FY2026ended Mar 31, 2026May 6, 2026before the open$631.00M+11.1%–Release
Q4 FY2025ended Dec 31, 2025Feb 11, 2026before the open–––Release
Q3 FY2025ended Sep 30, 2025Nov 5, 2025before the open$609.00M––Release
Q2 FY2025ended Jun 30, 2025Aug 6, 2025before the open$579.00M+7.8%–Release
Q1 FY2025ended Mar 31, 2025May 8, 2025before the open$568.00M0.0%–Release
Q4 FY2024ended Dec 31, 2024Feb 11, 2025before the open$594.00M––Release
Q3 FY2024ended Sep 30, 2024Nov 6, 2024before the open–––Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024before the open$537.00M-0.2%–Release
Q1 FY2024ended Mar 31, 2024May 9, 2024before the open$568.00M-17.0%–Release
Q4 FY2023ended Dec 31, 2023Jan 8, 2024before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Royalty Pharma's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Interest paidnon-GAAPQ3 FY2026$175.00M–NewAug 5, 2026
Interest paidQ3 FY2026$175.00M–NewMay 6, 2026
Interest paidnon-GAAPFY2026$350.00M – $360.00M–LoweredAug 5, 2026
Interest paidFY2026$350.00M – $360.00M$350.00M – $360.00MLoweredMay 6, 2026
Payments for operating and professional costsnon-GAAPFY20265.5% – 6.5%–NewAug 5, 2026
Payments for operating and professional costsFY20265.5% – 6.5%–NewMay 6, 2026
Portfolio Receiptsnon-GAAPFY2026$3.40B – $3.50B$3.33B – $3.45BRaisedAug 5, 2026
Portfolio ReceiptsFY2026$3.28B – $3.43B–RaisedFeb 11, 2026
Royalty Receipts growthnon-GAAPFY2026+7% – +10%+4% – +8%RaisedAug 5, 2026
Royalty Receipts growthFY2026+3% – +8%–NewFeb 11, 2026

Guidance history

Every forecast Royalty Pharma put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 5, 2026Payments for operating and professional costsFY20265.5% – 6.5%New
Aug 5, 2026Royalty Receipts growthFY2026+7% – +10%Raised
Aug 5, 2026Portfolio ReceiptsFY2026$3.40B – $3.50BRaised
Aug 5, 2026Interest paidFY2026$350.00M – $360.00MLowered
Aug 5, 2026Interest paidQ3 FY2026$175.00MNew
May 6, 2026Payments for operating and professional costsFY20265.5% – 6.5%New
May 6, 2026Royalty Receipts growthFY2026+4% – +8%New
May 6, 2026Interest paidFY2026$350.00M – $360.00MLowered
May 6, 2026Portfolio ReceiptsFY2026$3.33B – $3.45BNew
May 6, 2026Interest paidQ3 FY2026$175.00MNew
Feb 11, 2026Royalty Receipts growthFY2026+3% – +8%New
Feb 11, 2026Portfolio ReceiptsFY2026$3.28B – $3.43BRaised
Nov 5, 2025Payments for operating and professional costsFY20259% – 9.5%Reaffirmed
Nov 5, 2025Portfolio Receipts growthFY2025+14% – +16%Raised
Nov 5, 2025Portfolio ReceiptsFY2025$3.20B – $3.25BRaised
Nov 5, 2025Interest paidFY2025$275.00MLowered
Nov 5, 2025interest paidFY2026$350.00M – $360.00MNew
Aug 6, 2025Payments for operating and professional costsFY20259% – 9.5%New
Aug 6, 2025Portfolio Receipts growthFY2025+9% – +12%New
Aug 6, 2025Portfolio ReceiptsFY2025$3.05B – $3.15BNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Royalty Pharma filed with the SEC as exhibits to Form 8-K or 6-K

  1. R oyalty Pharma reports second quarter 2026 results
    Results
  2. R oyalty Pharma reports first quarter 2026 results
    Results
  3. ROYALTY PHARMA REPORTS Q4 AND FULL YEAR 2025 RESULTS
    Results
  4. ROYALTY PHARMA REPORTS THIRD QUARTER 2025 RESULTS
    Results
  5. ROYALTY PHARMA REPORTS SECOND QUARTER 2025 RESULTS
    Results
  6. ROYALTY PHARMA REPORTS FIRST QUARTER 2025 RESULTS
    Results
  7. ROYALTY PHARMA REPORTS Q4 AND FULL YEAR 2024 RESULTS
    Results
  8. J.P. Morgan Healthcare Conference January 2025 2
    Update
  9. COMPANY’S EVOLUTION WITH ACQUISITION OF ITS EXTERNAL
    Update
  10. Acquiring the External Manager – A Transformative Step in RP’s Evolution January 10, 2025 2
    Update
  11. Event Name: Royalty Pharma PLC Internalization Transaction Call
    Update
  12. ROYALTY PHARMA TO HIGHLIGHT ACCOMPLISHMENTS AND PROVIDE BUSINESS UPDATE AT 43rd ANNUAL J.P.
    Results
  13. ROYALTY PHARMA REPORTS THIRD QUARTER 2024 RESULTS
    Results
  14. ROYALTY PHARMA REPORTS SECOND QUARTER 2024 RESULTS
    Results
  15. ROYALTY PHARMA REPORTS FIRST QUARTER 2024 RESULTS
    Results